BioSpectrum the business of Bio & Health Sciences ASIA EDITION

XtalPi secures $15 M funding

January 24, 2018 | News

It currently partners with top global pharmaceutical companies and research organizations and looks forward to expanding industry collaborations with both existing and new partners.



Computation-driven pharmaceutical technology company XtalPi Inc. has closed a Series B funding round of $15 million led by Sequoia China, with participation from Google and existing investor Tencent. XtalPi's existing investors also include ZhenFund and FreeS Fund. It currently partners with top global pharmaceutical companies and research organizations and looks forward to expanding industry collaborations with both existing and new partners.

XtalPi offers Intelligent Digital Drug Discovery and Development (ID4) that improves the efficiency, accuracy, and success rate of drug design, solid-form drug selection, and other critical aspects of preclinical drug development. In combining artificial intelligence, quantum physics, and high-performance cloud computing, XtalPi can quickly and accurately predict many important characteristics of small-molecule drugs and solid forms, thereby providing time-saving insights into the safety, stability, and efficacy of drug candidates.

Proceeds from this funding round will be used to develop new computational models built on big data generated from XtalPi's high-precision computing platform and to expand its business into adjacent areas along the pharmaceutical value chain. The investment will also support the construction of a prediction-driven research lab that integrates XtalPi's R&D platform with state-of-the-art wet-bench laboratory technologies. This hybrid computational-experimental facility will provide enhanced capabilities for the rational design of solid forms of drugs.